CytomX Therapeutics, Inc. is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.
The company announced in the following report that, “We anticipate filing an Investigational New Drug application (an “IND”), or similar regulatory filing, for CX-072 with the FDA or a foreign regulatory authority in the second half of 2016. CX-072 has in vivo efficacy comparable to published reference PD-L1-targeting antibodies in various animal models.” (Page 4) Read the full document.
CytomX Therapeutics, Inc. operates as an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer. The company was founded in September, 2010 and is headquartered in South San Francisco, CA. [Source: MarketWatch]
Company Website: http://cytomx.com